Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1492541
This article is part of the Research Topic Monitoring the Immune/Tumor Microenvironment to Improve Cancer Immunotherapy View all 6 articles

Establishment of a prognostic signature and immune infiltration characteristics for uterine corpus endometrial carcinoma based on a disulfidptosis/ferroptosis-associated signature

Provisionally accepted
Yong Huang Yong Huang 1Huibin Li Huibin Li 2*Zhifu Wei Zhifu Wei 3*He Wanshan He Wanshan 1Bin Chen Bin Chen 1*Shuang Cheng Shuang Cheng 4*Zhifang Zhao Zhifang Zhao 4Lv Deng Lv Deng 5*Yu Lin Yu Lin 6*Xiaoshan Xiaoshan Hong Xiaoshan Xiaoshan Hong 1*
  • 1 Guangdong Province Women and Children Hospital, Guangzhou, China
  • 2 Department of pathology, Guangdong Women and Children Hospital, Guangdong, China
  • 3 The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, Guangdong Province, China
  • 4 Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China
  • 5 People's Hospital of Nanhai District, Foshan, China
  • 6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Background: Disulfidptosis and ferroptosis are two different programmed cell death pathways, and their potential therapeutic targets have important clinical prospects. Although there is an association between the two, the role of genes associated with these two forms of cell death in the development of endometrial cancer remains unclear.Methods: In this study, RNA sequencing (RNA-seq) and clinical data were obtained from public databases, and comprehensive analysis methods, including difference analysis, univariate Cox regression, and Least Absolute Shrinkage and Selection Operator (LASSO) analysis were used to construct a disulfidptosis/ferroptosis-related genes (DFRGs) prognostic signature. To further explore this new feature, pathway and functional analyses were performed, and the differences in gene mutation frequency and the level of immune cell infiltration between the high-and low-risk groups were studied. Finally, we validated the prognostic gene expression profile in clinical samples.We identified five optimal DFRGs that were differentially expressed and associated with the prognosis of uterine corpus endometrial carcinoma (UCEC). These genes include CDKN2A, FZD7, LCN2, ACTN4, and MYH10. Based on these DFRGs, we constructed a robust prognostic model with significantly lower overall survival in the high-risk group than in the low-risk group, with differences in tumor burden and immune invasion between the different risk groups. The expression of two key genes, ACTN4 and LCN2, was verified by immunohistochemistry and RT-qPCR.This study established a clinical prognostic model associated with disulfidptosis/ferroptosis-related genes, and the expression characteristics of key genes were validated in clinical samples. The comprehensive assessment of disulfidptosis and ferroptosis provides new insights to further guide patient clinical management and personalized treatment.

    Keywords: UCEC, Uterine corpus endometrial carcinoma, disulfidptosis, ferroptosis, Prognostic signature, Immune infiltration

    Received: 07 Sep 2024; Accepted: 07 Jan 2025.

    Copyright: © 2025 Huang, Li, Wei, Wanshan, Chen, Cheng, Zhao, Deng, Lin and Hong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Huibin Li, Department of pathology, Guangdong Women and Children Hospital, Guangdong, China
    Zhifu Wei, The Affiliated Shunde Hospital of Guangzhou Medical University, Foshan, Guangdong Province, China
    Bin Chen, Guangdong Province Women and Children Hospital, Guangzhou, China
    Shuang Cheng, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China
    Lv Deng, People's Hospital of Nanhai District, Foshan, China
    Yu Lin, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, China
    Xiaoshan Xiaoshan Hong, Guangdong Province Women and Children Hospital, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.